FILSPARI 200MG /400MG TAB (SPARSENTAN)
Price
FAQ's
Details
Patients Stories
Important Guide
Sparsentan, marketed under the brand name FILSPARI®, is an oral medication developed by Travere Therapeutics. It is approved for treating adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
🔹 Key Details
Manufacturer: Travere Therapeutics
Brand Name: FILSPARI®
Dosage Forms: Film-coated tablets in 200 mg and 400 mg strengths
Mechanism of Action: Dual antagonist of endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, aiming to reduce proteinuria and slow kidney function decline
Indications: Approved for the treatment of primary IgA nephropathy (IgAN) in adults at risk of disease progression
Dosing:
Start with 200 mg orally once daily for 14 days
Increase to 400 mg once daily, as tolerated